Baxdrostat
CinCor Pharma
[]
$cinc cincor pharma announces late-breaking presentation of phase 2 brightn data on baxdrostat in treatment-resistant hypertension at the 2022 american heart association scientific sessions 
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft